Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating long-term safety and efficacy of TEZ/IVA in cystic fibrosis patients with the F508del CFTR mutation has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TEZ/IVA (tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2021-11-26